SCHEMBL1307665

SCHEMBL1307665

O=C(Nc1cc(Br)ccc1C(=O)O)c1cccs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
GPR35 Q9HC97 1/20 0.56
ACLY P53396 1/20 0.56
MEN1 O00255 4/20 0.53
KMT2A Q03164 4/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TDP1 Q9NUW8 2/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.51
HDAC1 Q13547 2/20 0.50
KCNK2 O95069 1/20 0.50
KCNK10 P57789 1/20 0.50
HDAC3 O15379 1/20 0.50
GRIK1 P39086 1/20 0.49
TSHR P16473 1/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1308009 0.89 NPC1 (0.58) NPC1RAB9AGPR35MEN1KMT2A
SCHEMBL26998977 0.88 SMN1; SMN2 (0.55) NPC1RAB9AGPR35MEN1KMT2A
SCHEMBL29410738 0.88 SMN1; SMN2 (0.55) NPC1RAB9AGPR35MEN1KMT2A
SCHEMBL1307641 0.83 KCNMA1 (0.71) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL2269832 0.82 HDAC3 (0.74) NPC1RAB9AACLYMEN1KMT2A
SCHEMBL29642081 0.82 GPR35 (0.57) NPC1RAB9AGPR35MEN1KMT2A
SCHEMBL29642087 0.82 MAPK1 (0.71) NPC1RAB9AGPR35MEN1KMT2A
SCHEMBL38652227 0.81 RAB9A (0.74) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL13701150 0.81 RAB9A (0.74) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL2274595 0.79 LMNA (0.70) NPC1RAB9AMEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US claimed
US-8053454-B2 Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2011-11-08 US disclosed
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 EXELIXIS, INC. (US) 2009-02-12 US disclosed
WO-2004022525-A1 AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042918-A1 Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 PIM1, PIM3, PIM2 NPC1 3431/4885RAB9A 3031/4885GPR35 4703/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.